CD34 and Miyoshi myopathy: A Phase II biomarker-driven randomized study showed that in MM patients undergoing ASCT, propranolol shifted cell differentiation away from the myeloid-lineage bias and toward the CD34+ HSC-like profile, which leads to enhanced engraftment [39].